  |
|
 |
|
Case Report
| ||||||
| Acute generalized exanthematous pustulosis in the ambulatory care setting | ||||||
| LT Mark C. Hubbard1, LT John C. Walsh1, LCDR Megan A. Brelsford2 | ||||||
|
1M.D., Flight Surgeon, United States Navy, NAS Lemoore, Lemoore, CA, USA.
2D.O., Dermatology Physician, United States Navy, Naval Medical Center Portsmouth, Portsmouth, VA, USA. | ||||||
| ||||||
|
[HTML Full Text]
[PDF Full Text]
[Print This Article]
[Similar article in Pumed] [Similar article in Google Scholar] 
|
| How to cite this article |
| Hubbard MC, Walsh JC, Brelsford MA. Acute generalized exanthematous pustulosis in the ambulatory care setting. Int J Case Rep Images 2016;7(9):587–591. |
|
Abstract
|
|
Introduction:
Cutaneous symptoms are highly common in patients presenting to their primary care providers. However, severe cutaneous adverse reactions are most likely to present to the urgent care and emergency departments. Physicians practicing in routine primary care clinics should also be familiar with the presentation, early diagnosis, and treatment of severe drug reactions that may present to ambulatory clinics at the early clinical stages.
Case Report: Here we present a case of acute generalized exanthematous pustulosis which developed in the setting of exposure to unknown brands of sunscreen and aloe vera in an otherwise healthy 19-year-old male. Upon presenting to his primary care physician all possible inciting agents were discontinued and systemic involvement was rule out. He recovered completely within two weeks of eliminating all potential exposures to inciting agents. Conclusion: Proper triage, workup, treatment, and disposition are essential in cases of acute, rapidly progressive rashes, even when identification of the offending agent may not be apparent. Ambulatory care providers should be familiar with the diagnosis of acute generalized exanthematous pustulosis and its management, especially since many of the causative drugs are obtained on an outpatient basis. | |
|
Keywords:
Acute generalized exanthematous pustulosis (AGEP), Drug rash, Pustular rash, Severe adverse cutaneous reaction
| |
|
[HTML Full Text]
[PDF Full Text]
|
|
Author Contributions
LT Mark C. Hubbard – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data; Drafting the article; Final approval of the version to be published LT John C. Walsh – Substantial contributions to conception and design, Analysis and interpretation of data; Revising it critically for important intellectual content; Final approval of the version to be published LCDR Megan A. Brelsford – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data; Revising it critically for important intellectual content; Final approval of the version to be published |
|
Guarantor of submission
The corresponding author is the guarantor of submission. |
|
Source of support
None |
|
Conflict of interest
Authors declare no conflict of interest. |
|
Copyright
The authors are military service members. This work was prepared as part of their official duties. Title 17 USC 105 provides that "Copyright protection under this title is not available for any work of the United States Government." Title 17 USC 101 defines a United States Government work as a work prepared by a military service member or employee of the United States Government as part of that person's official duties." This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information. |
|
|